Short answer
Design for the 'continuum' of ability rather than binary states of 'healthy' or 'impaired.'
- Field
- User-Centred Design
- Source
- Alzheimer s & Dementia (2018)
- Method
- Framework Development / Consensus Study
- Evidence
- Strong effect
Shifting Alzheimer's diagnosis from symptomatic observation to biological biomarkers allows designers to identify and support users before functional impairment begins. This user-centred design research insight is drawn from a 2018 study published in Alzheimer s & Dementia. Using Framework development / consensus study, researchers explored how this design variable affects real-world outcomes. The key design takeaway: Design for the 'continuum' of ability rather than binary states of 'healthy' or 'impaired.'
Biomarker-based diagnostic frameworks improve interface accessibility for early-stage cognitive decline
Shifting Alzheimer's diagnosis from symptomatic observation to biological biomarkers allows designers to identify and support users before functional impairment begins.
Alzheimer s & Dementia · 2018
Key Findings
- 01Alzheimer's is defined as a biological construct (pathologic process) rather than a clinical syndrome (symptoms).
- 02The AT(N) system allows for a common language across research disciplines.
- 03Cognitive decline is a continuum that can be staged numerically (1-6) even before dementia symptoms appear.
Application
Design takeaway
Design for the 'continuum' of ability rather than binary states of 'healthy' or 'impaired.'
How to apply
Use the 6-stage numeric scale of cognitive impairment to test product usability across different stages of the Alzheimer's continuum.
Project actions
- 01Use this to justify why your 'Elderly Care' project focuses on early-stage intervention.
- 02Reference the 'AT(N)' categories when discussing user research for neurodegenerative conditions.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Provides a scientific basis for user segmentation
- +Moves away from subjective symptom reporting
Limitations
Students cannot access biomarker data; they must rely on the 'numeric scale' for user personas.
Reliability & validity
High reliability due to the consensus of major health organizations (NIA-AA), but validity for designers depends on translating biological markers into observable user behaviors.
Think critically
If we can predict cognitive decline biologically, does the designer have an ethical responsibility to 'hide' or 'reveal' assistive features to avoid stigmatizing the user?
Design Principles
"Proactive Inclusive Design: Utilizing biological data to trigger environmental or interface adaptations before functional failure occurs."
In design, User-Centred Design (design topics) relies on understanding the user's physiological and psychological limitations. This framework provides a biological 'early warning system' that allows designers to create proactive assistive technologies and inclusive interfaces for a demographic that was previously invisible until significant decline occurred.
What This Means for Your Design
Instead of waiting for someone to become forgetful to help them, we can use biological data to design tools that help them stay independent for longer.
How to use in your project
- 1.In Criterion A (Analysis of Problem), cite this framework to explain that your target user group includes those with 'preclinical' biological markers who require subtle cognitive scaffolding.
Add to My Project
Quick Cite
Paragraph starter
According to the NIA-AA Research Framework (Jack et al., 2018), Alzheimer's is now viewed as a biological continuum. This justifies a design approach that introduces cognitive supports early in the disease progression, specifically targeting users in the preclinical stages before significant functional impairment occurs.
Source
Alzheimer s & Dementia
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
journal · 2018
View sourceQuestions About This Research
- What does the research say about biomarker-based diagnostic frameworks improve interface accessibility for early-stage cognitive decline?
- Design for the 'continuum' of ability rather than binary states of 'healthy' or 'impaired.' Evidence: Alzheimer s & Dementia (2018).
- Why does "Biomarker-based diagnostic frameworks improve interface accessibility for early-stage cognitive decline" matter for design?
- In IB DT, User-Centred Design (Topic 7) relies on understanding the user's physiological and psychological limitations. This framework provides a biological 'early warning system' that allows designers to create proactive assistive technologies and inclusive interfaces for a demographic that was previously invisible until significant decline occurred.
- How can designers apply this research?
- Design for the 'continuum' of ability rather than binary states of 'healthy' or 'impaired.'
- What were the main findings?
- Alzheimer's is defined as a biological construct (pathologic process) rather than a clinical syndrome (symptoms).. The AT(N) system allows for a common language across research disciplines.. Cognitive decline is a continuum that can be staged numerically (1-6) even before dementia symptoms appear.
- What research method was used?
- Framework Development / Consensus Study.
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2018 journal from Alzheimer s & Dementia.
- What should I do differently in my next project?
- Use the 6-stage numeric scale of cognitive impairment to test product usability across different stages of the Alzheimer's continuum.
- What are the limitations?
- The framework is for research only and not yet intended for general clinical practice or routine product marketing.